Private equity firms who have a significant stake must be disappointed along with institutions after Centessa Pharmaceuticals plc's (NASDAQ:CNTA) market cap dropped by US$139m

Private equity firms who have a significant stake must be disappointed along with institutions after Centessa Pharmaceuticals plc's (NASDAQ:CNTA) market cap dropped by US$139m

Trade CNTA on Coinbase

Key Insights

  • The considerable ownership by private equity firms in Centessa Pharmaceuticals indicates that they collectively have a greater say in management and business strategy

  • A total of 5 investors have a majority stake in the company with 55% ownership

  • Institutions own 31% of Centessa Pharmaceuticals

If you want to know who really controls Centessa Pharmaceuticals plc (NASDAQ:CNTA), then you'll have to look at the makeup of its share registry. With 41% stake, private equity firms possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

While institutions, who own 31% shares weren’t spared from last week’s US$139m market cap drop, private equity firms as a group suffered the maximum losses

In the chart below, we zoom in on the different ownership groups of Centessa Pharmaceuticals.

View our latest analysis for Centessa Pharmaceuticals

ownership-breakdown
NasdaqGS:CNTA Ownership Breakdown March 12th 2024

What Does The Institutional Ownership Tell Us About Centessa Pharmaceuticals?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that Centessa Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Centessa Pharmaceuticals' historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
NasdaqGS:CNTA Earnings and Revenue Growth March 12th 2024

Our data indicates that hedge funds own 15% of Centessa Pharmaceuticals. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Looking at our data, we can see that the largest shareholder is Medicxi Ventures (UK) LLP with 20% of shares outstanding. For context, the second largest shareholder holds about 10% of the shares outstanding, followed by an ownership of 9.9% by the third-largest shareholder.

Our research also brought to light the fact that roughly 55% of the company is controlled by the top 5 shareholders suggesting that these owners wield significant influence on the business.